Eintrag weiter verarbeiten
Targeting ALK: The Ten Lives of a Tumor
Gespeichert in:
| Zeitschriftentitel: | Cancer Discovery |
|---|---|
| Personen und Körperschaften: | , |
| In: | Cancer Discovery, 6, 2016, 1, S. 20-21 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Versteeg, Rogier George, Rani E. Versteeg, Rogier George, Rani E. |
|---|---|
| author |
Versteeg, Rogier George, Rani E. |
| spellingShingle |
Versteeg, Rogier George, Rani E. Cancer Discovery Targeting ALK: The Ten Lives of a Tumor Oncology |
| author_sort |
versteeg, rogier |
| spelling |
Versteeg, Rogier George, Rani E. 2159-8274 2159-8290 American Association for Cancer Research (AACR) Oncology http://dx.doi.org/10.1158/2159-8290.cd-15-1411 <jats:title>Abstract</jats:title> <jats:p>Summary: In this issue, Infarinato and colleagues report the results of preclinical testing of a novel ALK/ROS1 inhibitor, PF-06463922, in neuroblastoma. This small-molecule inhibitor was shown to efficiently inhibit the growth of patient-derived and established neuroblastoma xenograft models expressing mutated ALK. Although the in vivo data are impressive and the authors suggest that clinical trials are warranted, the presented data also suggest that it is as yet too early to welcome the new drug as a magic bullet. Cancer Discov; 6(1); 20–1. ©2016 AACR.</jats:p> <jats:p>See related article by Infarinato et al., p. 96.</jats:p> Targeting ALK: The Ten Lives of a Tumor Cancer Discovery |
| doi_str_mv |
10.1158/2159-8290.cd-15-1411 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8yMTU5LTgyOTAuY2QtMTUtMTQxMQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8yMTU5LTgyOTAuY2QtMTUtMTQxMQ |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Zi4 DE-Gla1 DE-15 DE-Pl11 DE-Rs1 DE-14 DE-105 DE-Ch1 DE-L229 |
| imprint |
American Association for Cancer Research (AACR), 2016 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2016 |
| issn |
2159-8274 2159-8290 |
| issn_str_mv |
2159-8274 2159-8290 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
versteeg2016targetingalkthetenlivesofatumor |
| publishDateSort |
2016 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Cancer Discovery |
| source_id |
49 |
| title |
Targeting ALK: The Ten Lives of a Tumor |
| title_unstemmed |
Targeting ALK: The Ten Lives of a Tumor |
| title_full |
Targeting ALK: The Ten Lives of a Tumor |
| title_fullStr |
Targeting ALK: The Ten Lives of a Tumor |
| title_full_unstemmed |
Targeting ALK: The Ten Lives of a Tumor |
| title_short |
Targeting ALK: The Ten Lives of a Tumor |
| title_sort |
targeting alk: the ten lives of a tumor |
| topic |
Oncology |
| url |
http://dx.doi.org/10.1158/2159-8290.cd-15-1411 |
| publishDate |
2016 |
| physical |
20-21 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>Summary: In this issue, Infarinato and colleagues report the results of preclinical testing of a novel ALK/ROS1 inhibitor, PF-06463922, in neuroblastoma. This small-molecule inhibitor was shown to efficiently inhibit the growth of patient-derived and established neuroblastoma xenograft models expressing mutated ALK. Although the in vivo data are impressive and the authors suggest that clinical trials are warranted, the presented data also suggest that it is as yet too early to welcome the new drug as a magic bullet. Cancer Discov; 6(1); 20–1. ©2016 AACR.</jats:p>
<jats:p>See related article by Infarinato et al., p. 96.</jats:p> |
| container_issue |
1 |
| container_start_page |
20 |
| container_title |
Cancer Discovery |
| container_volume |
6 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792337769300754434 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:21:17.353Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Targeting+ALK%3A+The+Ten+Lives+of+a+Tumor&rft.date=2016-01-01&genre=article&issn=2159-8290&volume=6&issue=1&spage=20&epage=21&pages=20-21&jtitle=Cancer+Discovery&atitle=Targeting+ALK%3A+The+Ten+Lives+of+a+Tumor&aulast=George&aufirst=Rani+E.&rft_id=info%3Adoi%2F10.1158%2F2159-8290.cd-15-1411&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792337769300754434 |
| author | Versteeg, Rogier, George, Rani E. |
| author_facet | Versteeg, Rogier, George, Rani E., Versteeg, Rogier, George, Rani E. |
| author_sort | versteeg, rogier |
| container_issue | 1 |
| container_start_page | 20 |
| container_title | Cancer Discovery |
| container_volume | 6 |
| description | <jats:title>Abstract</jats:title> <jats:p>Summary: In this issue, Infarinato and colleagues report the results of preclinical testing of a novel ALK/ROS1 inhibitor, PF-06463922, in neuroblastoma. This small-molecule inhibitor was shown to efficiently inhibit the growth of patient-derived and established neuroblastoma xenograft models expressing mutated ALK. Although the in vivo data are impressive and the authors suggest that clinical trials are warranted, the presented data also suggest that it is as yet too early to welcome the new drug as a magic bullet. Cancer Discov; 6(1); 20–1. ©2016 AACR.</jats:p> <jats:p>See related article by Infarinato et al., p. 96.</jats:p> |
| doi_str_mv | 10.1158/2159-8290.cd-15-1411 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8yMTU5LTgyOTAuY2QtMTUtMTQxMQ |
| imprint | American Association for Cancer Research (AACR), 2016 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2016 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1, DE-L229 |
| issn | 2159-8274, 2159-8290 |
| issn_str_mv | 2159-8274, 2159-8290 |
| language | English |
| last_indexed | 2024-03-01T15:21:17.353Z |
| match_str | versteeg2016targetingalkthetenlivesofatumor |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 20-21 |
| publishDate | 2016 |
| publishDateSort | 2016 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Cancer Discovery |
| source_id | 49 |
| spelling | Versteeg, Rogier George, Rani E. 2159-8274 2159-8290 American Association for Cancer Research (AACR) Oncology http://dx.doi.org/10.1158/2159-8290.cd-15-1411 <jats:title>Abstract</jats:title> <jats:p>Summary: In this issue, Infarinato and colleagues report the results of preclinical testing of a novel ALK/ROS1 inhibitor, PF-06463922, in neuroblastoma. This small-molecule inhibitor was shown to efficiently inhibit the growth of patient-derived and established neuroblastoma xenograft models expressing mutated ALK. Although the in vivo data are impressive and the authors suggest that clinical trials are warranted, the presented data also suggest that it is as yet too early to welcome the new drug as a magic bullet. Cancer Discov; 6(1); 20–1. ©2016 AACR.</jats:p> <jats:p>See related article by Infarinato et al., p. 96.</jats:p> Targeting ALK: The Ten Lives of a Tumor Cancer Discovery |
| spellingShingle | Versteeg, Rogier, George, Rani E., Cancer Discovery, Targeting ALK: The Ten Lives of a Tumor, Oncology |
| title | Targeting ALK: The Ten Lives of a Tumor |
| title_full | Targeting ALK: The Ten Lives of a Tumor |
| title_fullStr | Targeting ALK: The Ten Lives of a Tumor |
| title_full_unstemmed | Targeting ALK: The Ten Lives of a Tumor |
| title_short | Targeting ALK: The Ten Lives of a Tumor |
| title_sort | targeting alk: the ten lives of a tumor |
| title_unstemmed | Targeting ALK: The Ten Lives of a Tumor |
| topic | Oncology |
| url | http://dx.doi.org/10.1158/2159-8290.cd-15-1411 |